Brokerages Expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to Announce $0.56 Earnings Per Share

Share on StockTwits

Equities research analysts expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to announce earnings of $0.56 per share for the current quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The lowest EPS estimate is $0.50 and the highest is $0.63. Eagle Pharmaceuticals posted earnings per share of $0.91 during the same quarter last year, which would suggest a negative year-over-year growth rate of 38.5%. The company is scheduled to announce its next earnings report on Thursday, November 7th.

On average, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $2.48 per share for the current financial year, with EPS estimates ranging from $2.25 to $2.79. For the next financial year, analysts anticipate that the firm will report earnings of $4.15 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.17. The company had revenue of $56.70 million during the quarter, compared to analysts’ expectations of $53.61 million. Eagle Pharmaceuticals had a return on equity of 24.10% and a net margin of 19.79%. The firm’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.99 EPS.

A number of research firms have recently commented on EGRX. ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 28th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 target price for the company in a research note on Wednesday, August 14th. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. Finally, Royal Bank of Canada restated a “buy” rating and issued a $66.00 target price on shares of Eagle Pharmaceuticals in a research note on Sunday, August 11th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $58.80.

Shares of EGRX traded down $1.59 on Friday, reaching $57.60. The stock had a trading volume of 85,485 shares, compared to its average volume of 178,529. The firm has a market capitalization of $789.03 million, a price-to-earnings ratio of 27.56 and a beta of 1.42. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.36 and a current ratio of 3.59. The company has a 50-day simple moving average of $56.22 and a 200-day simple moving average of $52.93. Eagle Pharmaceuticals has a 12-month low of $36.03 and a 12-month high of $70.13.

In related news, Director Hudson Executive Capital Lp sold 1,112 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $60.06, for a total transaction of $66,786.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 31.70% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of EGRX. Park West Asset Management LLC increased its position in Eagle Pharmaceuticals by 24.4% during the 2nd quarter. Park West Asset Management LLC now owns 1,300,000 shares of the specialty pharmaceutical company’s stock valued at $72,384,000 after buying an additional 254,689 shares in the last quarter. LSV Asset Management increased its position in Eagle Pharmaceuticals by 200.2% during the 1st quarter. LSV Asset Management now owns 250,004 shares of the specialty pharmaceutical company’s stock valued at $12,622,000 after buying an additional 166,715 shares in the last quarter. Invesco Ltd. increased its position in Eagle Pharmaceuticals by 50.4% during the 2nd quarter. Invesco Ltd. now owns 402,792 shares of the specialty pharmaceutical company’s stock valued at $22,427,000 after buying an additional 134,931 shares in the last quarter. Man Group plc increased its holdings in shares of Eagle Pharmaceuticals by 784.6% in the 2nd quarter. Man Group plc now owns 136,235 shares of the specialty pharmaceutical company’s stock worth $7,586,000 after purchasing an additional 120,835 shares in the last quarter. Finally, Federated Investors Inc. PA increased its holdings in shares of Eagle Pharmaceuticals by 326.8% in the 1st quarter. Federated Investors Inc. PA now owns 141,891 shares of the specialty pharmaceutical company’s stock worth $7,164,000 after purchasing an additional 108,649 shares in the last quarter. 97.51% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Featured Article: How are dividend achievers different from dividend aristocrats?

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.